The effect of combined treatment with dexamethasone and lenalidomide on natural killer–cell expression of NKp30, NKp46, and NKG2D in patients with myeloma. Serial blood samples were taken from myeloma patients before and during treatment with dexamethasone and lenalidomide as described in the text. Natural killer cell receptors were analyzed using a whole blood approach and flow cytometry. Results from NKG2D (A-B), NKp46 (C-D), and Nkp30 (E-F) are shown; in each case the percentage of NK cells positive for the receptor is shown as well as receptor density (assessed by mean channel fluorescence). In all cases, receptor expression is compared both between controls (n = 15, average age = 55) and patients (n = 9, average age = 63) and between patients before and during treatment.